Kevin M. Marks

8.2k total citations · 1 hit paper
14 papers, 4.2k citations indexed

About

Kevin M. Marks is a scholar working on Molecular Biology, Cancer Research and Genetics. According to data from OpenAlex, Kevin M. Marks has authored 14 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 4 papers in Cancer Research and 2 papers in Genetics. Recurrent topics in Kevin M. Marks's work include Epigenetics and DNA Methylation (5 papers), Cancer-related gene regulation (4 papers) and Cancer, Hypoxia, and Metabolism (3 papers). Kevin M. Marks is often cited by papers focused on Epigenetics and DNA Methylation (5 papers), Cancer-related gene regulation (4 papers) and Cancer, Hypoxia, and Metabolism (3 papers). Kevin M. Marks collaborates with scholars based in United States, Japan and Canada. Kevin M. Marks's co-authors include Stefan Größ, Katharine Yen, Valeria R. Fantin, Marie C. Keenan, Edward M. Driggers, Patrick S. Ward, Lenny Dang, David W. White, Mark Bittinger and Matthew G. Vander Heiden and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Blood.

In The Last Decade

Kevin M. Marks

14 papers receiving 4.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

2009 3.1k citations Lenny Dang, David W. White et al. Nature profile →

Peers

Countries citing papers authored by Kevin M. Marks

Since Specialization

Citations

This map shows the geographic impact of Kevin M. Marks's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin M. Marks with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin M. Marks more than expected).

Fields of papers citing papers by Kevin M. Marks

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin M. Marks. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin M. Marks. The network helps show where Kevin M. Marks may publish in the future.

Co-authorship network of co-authors of Kevin M. Marks

This figure shows the co-authorship network connecting the top 25 collaborators of Kevin M. Marks. A scholar is included among the top collaborators of Kevin M. Marks based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin M. Marks. Kevin M. Marks is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Title	Journal	Authors	Indexed citations
1	Abstract 3090: The MAT2A inhibitor, AG-270, combines with both taxanes and gemcitabine to yield enhanced anti-tumor activity in patient-derived xenograft models	Cancer Research	Marc L. Hyer, Peter Kalev et al.	3
2	Cancer Dependencies: PRMT5 and MAT2A in MTAP/p16-Deleted Cancers		Katya Marjon, Peter Kalev et al.	17
3	Abstract PR03: A phase 1 trial of AG-270 in patients with advanced solid tumors or lymphoma with homozygous MTAP deletion	Molecular Cancer Therapeutics	Rebecca S. Heist, Mrinal M. Gounder et al.	5
4	Abstract 2714: Targeting MAT2A in CDKN2A/MTAP-deleted cancers	Cancer Research	Katya Marjon, Peter Kalev et al.	1
5	Hematologic Malignancies Exhibit Selective Vulnerability to Inhibition of De Novo Pyrimidine Biosynthesis By AG-636, a Novel Inhibitor of Dihydroorotate Dehydrogenase in Phase 1 Clinical Trials	Blood	Danielle Ulanet, Victor Chubukov et al.	2
6	MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis	Cell Reports	Katya Marjon, Michael J. Cameron et al.	280
7	The Selectivity of Austocystin D Arises from Cell-Line-Specific Drug Activation by Cytochrome P450 Enzymes	Journal of Natural Products	Kevin M. Marks, Eun Sun Park et al.	34
8	Abstract 33: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate	Cancer Research	Valeria R. Fantin, Lenny Dang et al.	4
9	Cancer-associated IDH1 mutations produce 2-hydroxyglutarate	Nature	Lenny Dang, David W. White et al.	399
10	Cancer-associated IDH1 mutations produce 2-hydroxyglutarate breakdown →	Nature	Lenny Dang, David W. White et al.	3067
11	Chemical labeling strategies for cell biology	Nature Methods	Kevin M. Marks, Garry P. Nolan	200
12	In Vivo Targeting of Organic Calcium Sensors via Genetically Selected Peptides	Chemistry & Biology	Kevin M. Marks, Garry P. Nolan et al.	62
13	A general approach for chemical labeling and rapid, spatially controlled protein inactivation	Proceedings of the National Academy of Sciences	Kevin M. Marks, Patrick D. Braun et al.	83
14	Transformation-Defective Polyoma Middle T Antigen Mutants Defective in PLCγ, PI-3, or src Kinase Activation Enhance ERK2 Activation and Promote Retinoic Acid-Induced, Cell Differentiation Like Wild-Type Middle T	Experimental Cell Research	Andrew Yen, Van Cherington et al.	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact